****

**Figure 1) Vi-IgG and Vi-IgA titres in Nepalese children and U.K adults 28 days following Vi-TCV vaccination**Vi-IgG **(A)** and Vi-IgA **(B)** titres were measured in plasma from participants in the TyVAC Nepal study (n =17) and UK adults (n = 16) 28 days post Vi-TCV vaccination. Box plots show the median and interquartile range per group. Differences in ELISA titres between study sites were compared using the Wilcoxon test (\*\* p<0.01).

**C:\Users\mjohnson\OneDrive - Nexus365\R_laptop_backup\backup2\Documents\R_laptop\TyVAC_Bigexp\extra graphs\all_titres_age.tiff**

**Figure 2) Vi-IgG and Vi-IgA titres pre and 28 days post-vaccination in Nepalese children   
A-B)** Vi-IgG and Vi-IgA titres were measured across age groups of children aged 0-4 (n= 21), 5-9 (n= 24) and 10-15 years of age (n= 32) in Nepal prior to Vi-TCV vaccination and 28 days following Vi-TCV vaccination **(C –D)**. Box plots display the median and interquartile range for each age group. Differences in ELISA titres between age groups were compared using the Wilcoxon test. (\*\*\* = p <0.001, \*\* = p <0.01).

**C:\Users\mjohnson\OneDrive - Nexus365\R_laptop_backup\backup2\Documents\R_laptop\TyVAC_Bigexp\new_correlations\titre_elisa.tiff**

**Figure 3) Comparison of phagocytosis scores and Vi-antibody titres, pre and 28 days post-vaccination  
A-B)** Scatterplot displaying anti-Vi ADNP responses with Vi-IgA and Vi-IgG titres, colour of the points depicts the visit either pre, or 28 days post-vaccination. The phagocytic scores were calculated from bead+ neutrophils, multiplied by the MFI of the red fluorescent beads. Samples were run in technical duplicates and presented are the mean phagocytic scores per participant (n = 77).

C:\Users\mjohnson\OneDrive - Nexus365\R_laptop_backup\backup2\Documents\R_laptop\TyVAC_Bigexp\new_correlations\allg0_states.tiff

**Figure 4) Fc galactosylation states of Vi-IgG1 and VI-IgG2 with ADNP fold change 28 days following Vi-TCV vaccination  
A-C)** Correlation of the percentage of agalactosylated (G0), monogalactosylated (G1), and digalactosylated (G2) Vi-IgG1 antibodies at D28 with Vi-ADNP phagocytic score between baseline and D28, respectively (n =24). **D-F)** Correlation of the percentage of agalactosylated (G0), monogalactosylated (G1), and digalactosylated (G2) Vi-IgG2/3 antibodies at D28 with Vi-ADNP phagocytic score between baseline and D28, respectively. Shown for each graph are the Spearman’s Rho, and p-values for significance. In addition, the black line shows the linear regression, and the shaded area shows 95% confidence intervals for the model.

C:\Users\mjohnson\OneDrive - Nexus365\R_laptop_backup\backup2\Documents\R_laptop\TyVAC_Bigexp\new_correlations\fucosylation.tiff

**Figure 5) Fucosylation of Vi-IgG1 and Vi-IgG2/3 following Vi-TCV vaccination   
A-B)** Fucosylation of Vi-IgG1 and Vi-IgG2/3, 28 days after vaccination, respectively. Displayed is a histogram showing the range and frequency of the percentage of fucosylated Vi-antibodies across participants (n=24).